Abstracts tagged "cytokines and chemokines"

Abstract Number: 109 • 2019 ACR/ARP Annual Meeting
Targeting CD6 Expression Attenuates T Cell Activity in Murine Collagen Induced Arthritis
Yan Li ¹, Jeffrey H. Ruth ², Stephanie Rasmussen ³, Kalana S. Athukorala ², Daniel P. Weber ², M. Asif Amin ², Phillip Campbell ³, Nora Singer ⁴, David Fox⁵ and Feng Lin ¹, ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁴The MetroHealth System -Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence,University of Michigan, Ann Arbor, MI
Background/Purpose: CD6, an important regulator of T cell function, interacts with the ligands CD166 and CD318. We previously examined CD318 expression on synovial tissues (STs)…
Abstract Number: 1829 • 2019 ACR/ARP Annual Meeting
Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients
Melissa E. Munroe¹, Sarah Kleckner ¹, Wade DeJager ¹, Susan R. Macwana ¹, Joel Guthridge ², Eldon Jupe ³, Mohan Purushothaman ³, Sanjiv Sharma ³, Nancy Redinger ¹, Teresa Aberle ¹, Stan Kamp ¹, Cristina Arriens ², Eliza F. Chakravarty ², Joan T. Merrill ⁴ and Judith James ², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is marked by altered immune regulation linked to waxing and waning clinical disease activity. This study seeks to verify the alteration of inflammatory…
Abstract Number: 2008 • 2019 ACR/ARP Annual Meeting
Histone Lysine Methyltransferase MLL1 Regulates the Expression of Cytokines and Chemokines in Rheumatoid Arthritis Synovial Fibroblasts
Yasuto Araki¹, Keita Okamoto ¹, Yoshimi Aizaki ¹, Hiromi Oda ² and Toshihide Mimura ¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints. The inflammatory process causes the activation of synovial fibroblasts (SFs) and…
Abstract Number: 2784 • 2019 ACR/ARP Annual Meeting
Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients
Melissa E. Munroe¹, Carla J. Guthridge ¹, Sarah Kleckner ¹, Ly Tran ², Joel Guthridge ³, Debra J. Zack ⁴, Judith James ³ and Joan T. Merrill ⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Xencor, Inc., San Diego, CA, ⁵Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is typified by a wide spectrum of clinical manifestations and immune dysregulation. Corticosteroids are almost universally effective, but marked by unacceptable side effects.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].